Jade Biosciences (NASDAQ:JBIO) shares surged 20% on Tuesday after the clinical-stage biotech company unveiled JADE201, a new potentially best-in-class therapy for autoimmune diseases, alongside news of a $135 million private investment in public equity (PIPE) financing round.
JADE201 is an investigational half-life extended, afucosylated monoclonal antibody designed to target the B-cell activating factor receptor (BAFF-R). The company said the therapy is engineered to address the limitations of existing B cell–directed treatments by combining a dual mechanism of action with extended half-life technology, allowing for longer-lasting effects and less frequent dosing.
According to Jade, JADE201 leverages clinically validated BAFF-R targeting to deliver deeper and more durable B cell depletion with subcutaneous administration at wider intervals. Results from non-human primate studies showed dose-dependent receptor occupancy and sustained B cell depletion after a single dose.
“JADE201 reflects the progress we are making to build a complementary portfolio of therapies that modulate B-cell biology,” said Tom Frohlich, Chief Executive Officer of Jade. “JADE201 bolsters our portfolio of autoimmune disease therapies, which includes JADE101, a potentially best-in-class anti-APRIL monoclonal antibody being studied for the treatment of IgA nephropathy.”
The company plans to launch a first-in-human clinical trial for JADE201 in rheumatoid arthritis patients during the first half of 2026. The randomized, placebo-controlled Phase 1 trial will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics.
In addition to its therapeutic progress, Jade recently secured $135 million in gross proceeds through a PIPE financing, attracting major biotech investors such as Janus Henderson Investors, RA Capital Management, and Avidity Partners.
The announcement underscores Jade’s expanding focus on next-generation antibody therapies for autoimmune disorders and reinforces investor confidence in its advancing clinical pipeline.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.